Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer

References

• Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian ancer. Int J Gynecol Cancer. 2011;21:771–775.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019 May 17. [Epub ahead of print]. DOI:10.3322/caac.21559.
   PubMed Web of Science ®Google Scholar
• Armbruster S, Coleman RL, Rauh-Hain JA. Management and treatment of recurrent epithelial ovarian cancer. Hematol Oncol Clin North Am. 2018;32:965–982.
   PubMed Web of Science ®Google Scholar
• Pisano C, Bruni GS, Facchini G, et al. Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag. 2009;5:42–46.
   Google Scholar
• Sugiyama T, Yakushiji M, Noda K, et al. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology. 2000;58(1):31–37.
   PubMed Web of Science ®Google Scholar
• Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003;21(2):291–297.
   PubMed Web of Science ®Google Scholar
• Musa F, Pothuri B, Blank SV, et al. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2017;144(2):279–284.
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German society of gynecological oncology ovarian cancer study group. J Clin Oncol. 2011;29(2):242–248.
   PubMed Web of Science ®Google Scholar
• Meier W, Du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: A prospectively randomized phase III trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group (AGO-OVAR). Gynecol Oncol. 2009;114:199–205.
   PubMed Web of Science ®Google Scholar
• Sehouli J, Oskay-Ozcelik G. Current role and future aspects of topotecan in relapsed ovarian cancer. Curr Med Res Opin. 2009;25(3):639–651.
   PubMed Web of Science ®Google Scholar
• Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic–thirteenth Bruce F. Cain memorial award lecture. Cancer Res. 1995;55(4):753–760.
   PubMed Web of Science ®Google Scholar
• Acevedo-Morantes CY, Acevedo-Morantes MT, Suleiman-Rosado D, et al. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Drug Deliv. 2013;20:338–348.
   PubMed Web of Science ®Google Scholar
• Xie R, Mathijssen R, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites: A population analysis. J Clin Oncol. 2002;20:3293–3301.
   PubMed Web of Science ®Google Scholar
• Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 1989;28:4629–4638.
   PubMed Web of Science ®Google Scholar
• Rothenberg M, Kuhn J, Schaaf L, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol. 2001;12:1631–1641.
   PubMed Web of Science ®Google Scholar
• Alemany C. Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor. Curr Oncol Rep. 2014;16:367.
   PubMed Web of Science ®Google Scholar
• Gupta E, Lestingi T, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723–3725.
   PubMed Web of Science ®Google Scholar
• Seiter K. Toxicity of the topoisomerase I inhibitors. Expert Opin Drug Saf. 2005;4(1):45–53.
   PubMedGoogle Scholar
• Davis FF, Van Es T, Palczuk NC Non-immunogenic polypeptides. United States patent US. 1979;4:179–337
   Google Scholar
• Davis A, Tinker A, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624–631.
   PubMed Web of Science ®Google Scholar
• Pignata S, C Cecere S, Du BA, et al. Treatment of recurrent ovarian cancer. Ann Oncol. 2017 1;28(suppl_8):viii51–viii56.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–1308.
   PubMed Web of Science ®Google Scholar
• Grisham R, Moore KN, Gordon MS, et al. Phase Ib study of binimetib with paclitaxel in patients with platinum-resistant ovarian cancer: final results, potential biomarkers, and extreme responders. Clin Cancer Res. 2018: Published Online. 2018 May 29; DOI:10.1158/1078-0432.CCR-18-0494.
   Web of Science ®Google Scholar
• Konstantinopoulos PA, Munster P, Forero-Torez A, et al. Topacio: preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab. In: 49th Annual Meeting of the Society of Gynecologic Oncology. New Orleans, LA, 2018 Mar 24–27.
   Google Scholar
• Pubchem.ncbi.nlm.nih.gov. Etirinotecan Pegol. cited 2018 Oct 12 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/71300725
   Google Scholar
• Jameson G, Hamm J, Weiss G, et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res. 2013;19:268–278.
   PubMed Web of Science ®Google Scholar
• Hoch U, Staschen CM, Johnson RK, et al. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014;74:1125–1137.
   PubMed Web of Science ®Google Scholar
• Sy SKB, Chia YL, Gordi T, et al. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. Cancer Chemother Pharmacol. 2018;81:897–909.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency 2018. Etirinotecan Pegol assessment Report. cited 2018 Oct 12. Available from: https://www.ema.europa.eu/documents/assessment-report/onzeald-epar-refusal-public-assessment-report_en.pdf
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Vergote I, Garcia A, Micha J, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol. 2013;31:4046–4066.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynaecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419–423.
   PubMed Web of Science ®Google Scholar
• National cancer institute Bethesda, Maryland 20892: cancer therapy evaluation program: common terminology criteria for adverse events, version 3.0. cited 2018 Oct 12. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Rustin G, Vergote I, Micha J, et al. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2017;147:276–282.
   PubMed Web of Science ®Google Scholar
• Bamias A, Bamia C, Zagouri F, et al. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Oncology. 2013;84(3):158–165.
   PubMed Web of Science ®Google Scholar